药物洗脱支架术后的抗血小板治疗进展

被引：4

作者：

黄桂梅

李性天

机构：

[1] 武汉市汉口医院

来源：

中国药房 | 2011年 / 22卷 / 10期

关键词：

药物洗脱支架; 抗血小板治疗; 阿司匹林; 氯吡格雷;

D O I：

暂无

中图分类号：

R541.4 [冠状动脉（粥样）硬化性心脏病（冠心病）];

学科分类号：

摘要：

目的:总结药物洗脱支架术后抗血小板治疗方案及处置要点,改善急性冠脉综合征患者的长期预后。方法:就国外医学界在药物洗脱支架术后抗血小板治疗领域近年的进展作一综述。结果与结论:植入药物洗脱支架或裸金属支架的急性冠脉综合征患者,术后预防的核心是长期、稳定地控制可能发生的心肌缺血事件并最大程度减少出血危险。经典防治方案是采用阿司匹林和氯吡格雷的双联抗血小板治疗。过早停药可带来严重后果,确保治疗依从性是医师和患者的共同责任。一些新型药物具有更迅速、均衡和有效的血小板抑制效果,有明显的治疗优势。

引用

页码：927 / 930

页数：4

共 11 条

[1] RP-HPLC法同时测定人血清中氯吡格雷和阿司匹林的浓度 [J].

王夏芹 ;

黄晓晖 ;

陈纭 ;

唐海沁 ;

郑青山 ;

金涌 ;

李俊 .

中国药房, 2010, 21 (02) :122-124

[2] Platelet Reactivity After Clopidogrel Treatment Assessed With Point-of-Care Analysis and Early Drug-Eluting Stent Thrombosis [J].

Sibbing, Dirk ;

Braun, Siegmund ;

Morath, Tanja ;

Mehilli, Julinda ;

Vogt, Wolfgang ;

Schoemig, Albert ;

Kastrati, Adnan ;

von Beckerath, Nicolas .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 53 (10) :849-856

[3] Barriers to Clopidogrel Adherence Following Placement of Drug-Eluting Stents [J].

Pallares, Maria Jose ;

Powers, Eric R. ;

Zwerner, Peter L. ;

Fowler, Andrew ;

Reeves, Rodney ;

Nappi, Jean M. .

ANNALS OF PHARMACOTHERAPY, 2009, 43 (02) :259-267

[4]

Cardiovascular Death and Nonfatal Myocardial Infarction in Acute Coronary Syndrome Patients Receiving Coronary Stenting Are Predicted by Residual Platelet Reactivity to ADP Detected by a Point-of-Care Assay: A 12-Month Follow-Up[J] . Rossella Marcucci,Anna Maria Gori,Rita Paniccia,Betti Giusti,Serafina Valente,Cristina Giglioli,Piergiovanni Buonamici,David Antoniucci,Rosanna Abbate,Gian Franco Gensini.Circulation . 2009 (2)

[5] Impact of "Nuisance" Bleeding on Clopidogrel Compliance in Patients Undergoing Intracoronary Drug-Eluting Stent Implantation [J].

Roy, Probal ;

Bonello, Laurent ;

Torguson, Rebecca ;

de Labriolle, Axel ;

Lemesle, Gilles ;

Slottow, Tina L. Pinto ;

Steinberg, Daniel H. ;

Kaneshige, Kimberly ;

Xue, Zhenyi ;

Satler, Lowell F. ;

Kent, Kenneth M. ;

Suddath, William O. ;

Pichard, Augusto D. ;

Lindsay, Joseph ;

Waksman, Ron .

AMERICAN JOURNAL OF CARDIOLOGY, 2008, 102 (12) :1614-1617

[6]

Design and rationale of CURRENT-OASIS 7: A randomized, 2 × 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non–ST-elevation acute coronary syndromes managed with an early invasive strategy[J] . Shamir R. Mehta,Jean-Pierre Bassand,Susan Chrolavicius,Rafael Diaz,Keith A.A. Fox,Christopher B. Granger,Sanjit Jolly,Hans-Jurgen Rupprecht,Petr Widimsky,Salim Yusuf.American Heart Journal . 2008 (6)

[7]

Clopidogrel 600-Mg Double Loading Dose Achieves Stronger Platelet Inhibition Than Conventional Regimens[J] . Philippe L. L’Allier,Grégory Ducrocq,Nicolas Pranno,Stéphane Noble,Reda Ibrahim,Jean C. Grégoire,Fabian Azzari,Anna Nozza,Colin Berry,Serge Doucet,Benoit Labarthe,Pierre Théroux,Jean-Claude Tardif.Journal of the American College of Cardiology . 2008 (11)

[8]

Clopidogrel Effect on Platelet REactivity in Patients With Stent Thrombosis[J] . Paul A. Gurbel,Kevin P. Bliden,Waiel Samara,Jason A. Yoho,Kevin Hayes,Mulugeta Z. Fissha,Udaya S. Tantry.Journal of the American College of Cardiology . 2005 (10)

[9]

Platelet Reactivity in Patients and Recurrent Events Post-Stenting[J] . Paul A. Gurbel,Kevin P. Bliden,Kirk Guyer,Peter W. Cho,Kazi A. Zaman,Rolf P. Kreutz,Ashwani K. Bassi,Udaya S. Tantry.Journal of the American College of Cardiology . 2005 (10)

[10]

A clinical trial comparing treatment with can-grelor to usual care in subjects who require percutaneous coronary intervention. http://clinicaltrials-nccs.nlm.nih.gov/ct/show/NCT00385138 . 2009

← 1 2 →